15.92 USD
-0.33 (-2.03%)
We assign a fundamental rating of 6 out of 10 to AUPH. AUPH was compared to 530 industry peers in the Biotechnology industry. AUPH is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. AUPH is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, AUPH could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
In the past year AUPH was profitable.
AUPH had a positive operating cash flow in the past year.
In the past 5 years AUPH reported 4 times negative net income.
In the past 5 years AUPH reported 4 times negative operating cash flow.
1.2 Ratios
AUPH's Return On Assets of 14.76% is amongst the best of the industry. AUPH outperforms 95.28% of its industry peers.
AUPH's Return On Equity of 21.28% is amongst the best of the industry. AUPH outperforms 96.60% of its industry peers.
With an excellent Return On Invested Capital value of 14.89%, AUPH belongs to the best of the industry, outperforming 95.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.76% | ||
| ROE | 21.28% | ||
| ROIC | 14.89% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of AUPH (29.28%) is better than 95.47% of its industry peers.
Looking at the Operating Margin, with a value of 32.73%, AUPH belongs to the top of the industry, outperforming 96.79% of the companies in the same industry.
With an excellent Gross Margin value of 88.93%, AUPH belongs to the best of the industry, outperforming 90.94% of the companies in the same industry.
In the last couple of years the Gross Margin of AUPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.73% | ||
| PM (TTM) | 29.28% | ||
| GM | 88.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
2. Health
2.1 Basic Checks
AUPH has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, AUPH has less shares outstanding
The number of shares outstanding for AUPH has been increased compared to 5 years ago.
The debt/assets ratio for AUPH has been reduced compared to a year ago.
2.2 Solvency
AUPH has an Altman-Z score of 7.54. This indicates that AUPH is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of AUPH (7.54) is better than 77.17% of its industry peers.
AUPH has a debt to FCF ratio of 0.60. This is a very positive value and a sign of high solvency as it would only need 0.60 years to pay back of all of its debts.
The Debt to FCF ratio of AUPH (0.60) is better than 94.91% of its industry peers.
AUPH has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
AUPH's Debt to Equity ratio of 0.15 is on the low side compared to the rest of the industry. AUPH is outperformed by 65.09% of its industry peers.
Although AUPH does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | 0.6 | ||
| Altman-Z | 7.54 |
ROIC/WACC1.94
WACC7.67%
2.3 Liquidity
AUPH has a Current Ratio of 5.76. This indicates that AUPH is financially healthy and has no problem in meeting its short term obligations.
AUPH has a Current ratio of 5.76. This is in the better half of the industry: AUPH outperforms 60.19% of its industry peers.
AUPH has a Quick Ratio of 5.17. This indicates that AUPH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AUPH (5.17) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 609.09% over the past year.
AUPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.62%.
Measured over the past years, AUPH shows a very strong growth in Revenue. The Revenue has been growing by 279.17% on average per year.
EPS 1Y (TTM)609.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%8.41%
3.2 Future
AUPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 70.13% yearly.
The Revenue is expected to grow by 14.93% on average over the next years. This is quite good.
EPS Next Y772.67%
EPS Next 2Y225.53%
EPS Next 3Y128.43%
EPS Next 5Y70.13%
Revenue Next Year19.09%
Revenue Next 2Y17.76%
Revenue Next 3Y16.39%
Revenue Next 5Y14.93%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
AUPH is valuated quite expensively with a Price/Earnings ratio of 28.43.
Based on the Price/Earnings ratio, AUPH is valued cheaper than 93.02% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.92, AUPH is valued at the same level.
With a Price/Forward Earnings ratio of 16.69, AUPH is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AUPH indicates a rather cheap valuation: AUPH is cheaper than 95.28% of the companies listed in the same industry.
AUPH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.43 | ||
| Fwd PE | 16.69 |
4.2 Price Multiples
AUPH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AUPH is cheaper than 95.09% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AUPH indicates a rather cheap valuation: AUPH is cheaper than 96.04% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.51 | ||
| EV/EBITDA | 14.88 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AUPH's earnings are expected to grow with 128.43% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y225.53%
EPS Next 3Y128.43%
5. Dividend
5.1 Amount
AUPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:AUPH (12/29/2025, 12:32:49 PM)
15.92
-0.33 (-2.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners50.74%
Inst Owner Change10.72%
Ins Owners1.92%
Ins Owner Change-0.55%
Market Cap2.10B
Revenue(TTM)265.81M
Net Income(TTM)77.84M
Analysts81.54
Price Target17.05 (7.1%)
Short Float %6.91%
Short Ratio5.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.94%
Min EPS beat(2)6.95%
Max EPS beat(2)40.93%
EPS beat(4)4
Avg EPS beat(4)66.5%
Min EPS beat(4)6.95%
Max EPS beat(4)161.28%
EPS beat(8)7
Avg EPS beat(8)112.72%
EPS beat(12)11
Avg EPS beat(12)88.48%
EPS beat(16)14
Avg EPS beat(16)70.43%
Revenue beat(2)2
Avg Revenue beat(2)7.29%
Min Revenue beat(2)6.84%
Max Revenue beat(2)7.75%
Revenue beat(4)2
Avg Revenue beat(4)3.01%
Min Revenue beat(4)-2.09%
Max Revenue beat(4)7.75%
Revenue beat(8)5
Avg Revenue beat(8)4.09%
Revenue beat(12)9
Avg Revenue beat(12)8.29%
Revenue beat(16)13
Avg Revenue beat(16)10.25%
PT rev (1m)6.36%
PT rev (3m)42.68%
EPS NQ rev (1m)8.34%
EPS NQ rev (3m)41.31%
EPS NY rev (1m)18.77%
EPS NY rev (3m)18.77%
Revenue NQ rev (1m)2.67%
Revenue NQ rev (3m)6.72%
Revenue NY rev (1m)3.77%
Revenue NY rev (3m)4.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.43 | ||
| Fwd PE | 16.69 | ||
| P/S | 7.9 | ||
| P/FCF | 17.51 | ||
| P/OCF | 17.48 | ||
| P/B | 5.74 | ||
| P/tB | 5.8 | ||
| EV/EBITDA | 14.88 |
EPS(TTM)0.56
EY3.52%
EPS(NY)0.95
Fwd EY5.99%
FCF(TTM)0.91
FCFY5.71%
OCF(TTM)0.91
OCFY5.72%
SpS2.02
BVpS2.77
TBVpS2.74
PEG (NY)0.04
PEG (5Y)N/A
Graham Number5.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.76% | ||
| ROE | 21.28% | ||
| ROCE | 19.28% | ||
| ROIC | 14.89% | ||
| ROICexc | 67.33% | ||
| ROICexgc | 70.07% | ||
| OM | 32.73% | ||
| PM (TTM) | 29.28% | ||
| GM | 88.93% | ||
| FCFM | 45.1% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
F-Score9
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | 0.6 | ||
| Debt/EBITDA | 0.52 | ||
| Cap/Depr | 1.21% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.83% | ||
| Profit Quality | 154% | ||
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.17 | ||
| Altman-Z | 7.54 |
F-Score9
WACC7.67%
ROIC/WACC1.94
Cap/Depr(3y)6.1%
Cap/Depr(5y)121.69%
Cap/Sales(3y)0.25%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)609.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130%
EPS Next Y772.67%
EPS Next 2Y225.53%
EPS Next 3Y128.43%
EPS Next 5Y70.13%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%8.41%
Revenue Next Year19.09%
Revenue Next 2Y17.76%
Revenue Next 3Y16.39%
Revenue Next 5Y14.93%
EBIT growth 1Y448.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9822.78%
EBIT Next 3Y402.81%
EBIT Next 5YN/A
FCF growth 1Y414.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y421.82%
OCF growth 3YN/A
OCF growth 5YN/A
AURINIA PHARMACEUTICALS INC / AUPH FAQ
Can you provide the ChartMill fundamental rating for AURINIA PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 6 / 10 to AUPH.
Can you provide the valuation status for AURINIA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 7 / 10 to AURINIA PHARMACEUTICALS INC (AUPH). This can be considered as Undervalued.
What is the profitability of AUPH stock?
AURINIA PHARMACEUTICALS INC (AUPH) has a profitability rating of 5 / 10.
What are the PE and PB ratios of AURINIA PHARMACEUTICALS INC (AUPH) stock?
The Price/Earnings (PE) ratio for AURINIA PHARMACEUTICALS INC (AUPH) is 28.43 and the Price/Book (PB) ratio is 5.74.
What is the expected EPS growth for AURINIA PHARMACEUTICALS INC (AUPH) stock?
The Earnings per Share (EPS) of AURINIA PHARMACEUTICALS INC (AUPH) is expected to grow by 772.67% in the next year.